期刊
CURRENT ONCOLOGY
卷 19, 期 -, 页码 S45-S51出版社
MULTIMED INC
DOI: 10.3747/co.19.1113
关键词
NSCLC; primary resistance; secondary resistance
类别
资金
- Roche
- AstraZeneca
Non-small-cell lung cancer (NSCLC) constitutes about 85% of all lung cancers. Approximately 50% of patients diagnosed with NSCLC present with advanced disease (stage III or IV) that is not amenable to curative treatment. The number of patients with stage IIIB or IV disease who are alive at 1 year after diagnosis has increased from 10% in the untreated population in the early 1980s to 50% in patients with a good performance status receiving treatment today. However, those statistics remain dismal, and the two dominant reasons are the large number of patients diagnosed with advanced-stage disease and the observed primary or secondary resistance to current therapies. The present article addresses the question of drug resistance in lung cancer, focusing on subjects that are currently topical and under intense scrutiny.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据